Literature DB >> 12416809

Efficacy of systemic ceftiofur as a therapy for severe clinical mastitis in dairy cattle.

R J Erskine1, P C Bartlett, J L VanLente, C R Phipps.   

Abstract

The objectives of this study were to determine the efficacy of intramuscular administration of ceftiofur to reduce the incidence of case-related death and culling following severe clinical mastitis in lactating dairy cattle. A total of 104 cows with severe clinical mastitis (systemic signs) were enrolled in the study and randomly assigned to one of two treatment groups. Immediately after detection of the case, one group was administered 2.2 mg/kg of ceftiofur intramuscularly, and the dose repeated at 24-h intervals for a total of five doses. The second group of cows did not receive systemic antibacterial therapy. Additionally, all cows in both treatment groups received intramammary pirlimycin (Pirsue) in the affected quarter every 24 h for a total of up to three doses. Also at the onset of the case, all cows on the trial were administered a supportive therapeutic regimen of fluids and anti-inflammatory agents that varied from farm to farm, but was standard within each herd at the discretion of the herd manager and veterinarian. Of all cases 14/104 (13.5%) resulted in a lost cow (died or culled). The proportion of cases that resulted in a lost cow and were treated with ceftiofur (4/51; 7.8%) did not statistically differ from cows that were not treated with ceftiofur (10/53; 18.9%). However, the proportion of cases that resulted in lost cows was higher for those cases that yielded a coliform organism on culture (14/56; 25.0%) than cases that did not yield coliforms (0/48; 0.0%; P < 0.001). Thus, among coliform cases, cows that were not treated with ceftiofur were more likely to be culled or die (10/27, 37.0%; P < 0.05) than cows treated with ceftiofur (4/29, 13.8%). We conclude that intramuscular administration of ceftiofur did not affect the outcome of severe clinical mastitis when all etiologic agents are included in the analysis. However, for severe clinical mastitis cases caused by coliform organisms, ceftiofur therapy reduced the proportion of cases that resulted in cow death or culling. This benefit may be realized because of the amelioration of bacteremic-related pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416809     DOI: 10.3168/jds.S0022-0302(02)74340-3

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  20 in total

1.  CTX-M1 ESBL-producing Klebsiella pneumoniae subsp. pneumoniae isolated from cases of bovine mastitis.

Authors:  Clara Locatelli; Licia Scaccabarozzi; Giuliano Pisoni; Paolo Moroni
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

Review 2.  Mastitis therapy and antimicrobial susceptibility: a multispecies review with a focus on antibiotic treatment of mastitis in dairy cattle.

Authors:  John Barlow
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-09       Impact factor: 2.673

3.  Prevalence and risk factors of subclinical mastitis in lactating dairy cows in north and south regions of Bangladesh.

Authors:  Swapan Chandra Sarker; Mst Sonia Parvin; A K M Anisur Rahman; Md Taohidul Islam
Journal:  Trop Anim Health Prod       Date:  2012-12-31       Impact factor: 1.559

4.  Diverse β-lactam antibiotic-resistant bacteria and microbial community in milk from mastitic cows.

Authors:  Zhengxin Ma; Shinyoung Lee; Peixin Fan; Yuting Zhai; Jaehyun Lim; Klibs N Galvão; Corwin Nelson; Kwangcheol Casey Jeong
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-15       Impact factor: 4.813

5.  Antimicrobials use and their indications in dairy farm and individual farmer production conditions in southern India.

Authors:  Deepak Sharma; Ayyasamy Manimaran; Arumugam Kumaresan; Muniandy Sivaram; Duraisamy Rajendran
Journal:  Trop Anim Health Prod       Date:  2021-12-28       Impact factor: 1.559

6.  Acute coliform mastitis in buffaloes (Bubalus bubalis): clinical findings and treatment outcomes.

Authors:  Sabry A El-Khodery; Salama A Osman
Journal:  Trop Anim Health Prod       Date:  2008-02       Impact factor: 1.559

7.  Phenotypic, antimicrobial susceptibility profile and virulence factors of Klebsiella pneumoniae isolated from buffalo and cow mastitic milk.

Authors:  Kamelia M Osman; Hany M Hassan; Ahmed Orabi; Ahmed S T Abdelhafez
Journal:  Pathog Glob Health       Date:  2014-06-10       Impact factor: 2.894

8.  An Understanding of the Global Status of Major Bacterial Pathogens of Milk Concerning Bovine Mastitis: A Systematic Review and Meta-Analysis (Scientometrics).

Authors:  Paramanandham Krishnamoorthy; Kuralayanapalya P Suresh; Kavitha S Jayamma; Bibek R Shome; Sharanagouda S Patil; Raghavendra G Amachawadi
Journal:  Pathogens       Date:  2021-04-30

9.  Treatment of mastitis during lactation.

Authors:  S Pyörälä
Journal:  Ir Vet J       Date:  2009-04-01       Impact factor: 2.146

10.  Activity of sEH and Oxidant Status during Systemic Bovine Coliform Mastitis.

Authors:  Vengai Mavangira; Matthew J Kuhn; Angel Abuelo; Christophe Morisseau; Bruce D Hammock; Lorraine M Sordillo
Journal:  Antioxidants (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.